Novo Nordisk has experienced an IT security incident involving unauthorized access to some internal systems. The company is investigating with cybersecurity experts and has temporarily taken certain systems offline to protect its environment. While core business operations remain unaffected, some non-public data, including personal information, was copied without authorization. Novo Nordisk is informing affected parties and prioritizing system security and patient support as it works to restore affected systems safely.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
